These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 33082704)

  • 1. Worldwide HTA access to ICER's cost-effectiveness models.
    PharmacoEcon Outcomes News; 2020; 864(1):3. PubMed ID: 33082704
    [No Abstract]   [Full Text] [Related]  

  • 2. Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?
    Cohen JT; Silver MC; Ollendorf DA; Neumann PJ
    Value Health; 2019 Dec; 22(12):1396-1401. PubMed ID: 31806196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER's Cost-Effectiveness Estimates.
    Breslau RM; Cohen JT; Ollendorf DA; Neumann PJ
    Pharmacoecon Open; 2022 Nov; 6(6):893-895. PubMed ID: 35871128
    [No Abstract]   [Full Text] [Related]  

  • 4. Challenges with Forecasting Budget Impact: A Case Study of Six ICER Reports.
    Snider JT; Sussell J; Tebeka MG; Gonzalez A; Cohen JT; Neumann P
    Value Health; 2019 Mar; 22(3):332-339. PubMed ID: 30832971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ICER's second update to pricing models of remdesivir for COVID-19.
    PharmacoEcon Outcomes News; 2020; 867(1):2. PubMed ID: 33262564
    [No Abstract]   [Full Text] [Related]  

  • 6. ICER's Revised Value Assessment Framework for 2017-2019: A Critique.
    Neumann PJ; Cohen JT
    Pharmacoeconomics; 2017 Oct; 35(10):977-980. PubMed ID: 28791663
    [No Abstract]   [Full Text] [Related]  

  • 7. ICER's timelines for assessments extended due to COVID-19.
    PharmacoEcon Outcomes News; 2020; 850(1):1. PubMed ID: 32288506
    [No Abstract]   [Full Text] [Related]  

  • 8. Addressing the health technology assessment of biosimilar pharmaceuticals.
    Stewart A; Aubrey P; Belsey J
    Curr Med Res Opin; 2010 Sep; 26(9):2119-26. PubMed ID: 20649394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
    Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
    Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costo Efectividad del Tratamiento de Tumores Neuroendócrinos Pancreáticos Avanzados no Operables con Sunitinib en México.
    Muciño Ortega E; Chi-Chan A; Peniche-Otero G; Gutiérrez-Colín CI; Herrera-Rojas J; Galindo-Suárez RM
    Value Health Reg Issues; 2012 Dec; 1(2):150-155. PubMed ID: 29702894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding HTA - Correcting a Misattribution, Clarifying the Scope of HTA and CEA Comment on "Ethics in HTA: Examining the 'Need for Expansion'".
    Culyer AJ
    Int J Health Policy Manag; 2019 Dec; 8(12):732-733. PubMed ID: 31779302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
    Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
    Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The economic value of vaccinations: a systematic review of Italian economic evaluations and HTA reports].
    Di Nardo F; Boccalini S; Calabrò GE; Marcellusi A; Ruggeri M; Bonanni P; Vitali R; Capannini E; Mennini FS; Cicchetti A; Panatto D; Gasparini R; Ricciardi W; De Waure C
    Ig Sanita Pubbl; 2017; 73(5):453-471. PubMed ID: 29433132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. To HTA or Not to HTA: Identifying the Factors Influencing the Rapid Review Outcome in Ireland.
    Murphy A; Redmond S
    Value Health; 2019 Apr; 22(4):385-390. PubMed ID: 30975388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timely, consistent, transparent assessment of market access evidence: implementing tools based on the HTA Core Model® in a pharmaceutical company.
    Ducournau P; Irl C; Tatt I; McCarvil M; Gyldmark M
    Int J Technol Assess Health Care; 2019 Jan; 35(1):10-16. PubMed ID: 30789111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hospital-based health technology assessment in France: how to proceed to evaluate innovative medical devices?].
    Martelli N; van den Brink H; Denies F; Dervaux B; Germe AF; Prognon P; Pineau J
    Ann Pharm Fr; 2014 Jan; 72(1):3-14. PubMed ID: 24438663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linking the Regulatory and Reimbursement Processes for Medical Devices: The Need for Integrated Assessments.
    Ciani O; Wilcher B; van Giessen A; Taylor RS
    Health Econ; 2017 Feb; 26 Suppl 1():13-29. PubMed ID: 28139087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PERSPECTIVE: SOME CONCLUSIONS FROM MY LIFE IN HEALTH TECHNOLOGY ASSESSMENT.
    Banta HD
    Int J Technol Assess Health Care; 2018 Jan; 34(2):131-133. PubMed ID: 29609663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.